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Objective. To examine the role of the variants of
the PTPN22 and HLA–DRB1 genes as predictors of
mortality in inflammatory polyarthritis (IP) and rheu-
matoid arthritis (RA).
Methods. Patients were recruited from a primary
care–based inception cohort of patients with IP and
were followed up prospectively. For patients who died,
the cause and date of death was obtained. Cox propor-
tional hazards regression models were used to assess
the association of the HLA–DRB1 (including the shared
epitope [SE]) and PTPN22 genes with the risk of death
from all causes and from cardiovascular disease (CVD)
and to assess the interactions between SE, smoking, and
anti–cyclic citrullinated peptide (anti-CCP) status, ad-
justed by age at symptom onset and sex.
Results. DNA samples were available from 1,022
IP patients. During followup, 751 of them (74%) satis-
fied the American College of Rheumatology 1987 crite-
ria for RA, and 242 of them (24%) died. Carriage of 2
copies of SE alleles predicted death from all causes
(hazard ratio [HR] 1.57 [95% confidence interval (95%
CI) 1.1–2.2]) and from CVD (HR 1.68 [95% CI 1.1–
2.7]). This effect was most marked for individuals with
the HLA–DRB1*01/*04 combination. An interaction of
smoking, SE alleles, and anti-CCP antibodies was ob-
served and was associated with the greatest risk of death
from CVD (HR 7.81 [95% CI 2.6–23.2]). No association
of the PTPN22 gene with mortality was detected.
Conclusion. SE alleles, particularly compound
heterozygotes, are associated with death from all causes
and from CVD, independently of autoantibody status.
However, the combination of SE, smoking, and anti-
CCP antibodies is associated with a high risk of prema-
ture death in patients with IP and RA, which raises the
possibility of a targeted strategy to prevent CVD in these
patients.
It is being increasingly recognized that people
with rheumatoid arthritis (RA) are at greater risk of
premature death as compared with the general popu-
lation and that cardiovascular disease (CVD) is re-
sponsible for most of this excess mortality (for review,
see ref. 1). One hypothesis is that inflammation may
promote atherosclerosis. Indeed, elevation of the
C-reactive protein (CRP) level, a marker of systemic
inflammation, has been shown to predict CVD in the
general population (2). Previous studies in patients
with RA have also confirmed that it is those with the
most active inflammatory disease who carry the great-
est increased risk of death from all causes and, in
particular, death from CVD (3–6). However, in-
creased mortality rates are not seen in all diseases
with a high inflammatory burden, such as Crohn’s
disease, for example, suggesting that other factors also
play a role. To explore other possible pathways, we
investigated whether genetic variants associated with
RA susceptibility and/or severity may also predict
all-cause and CVD mortality in these patients.
The major susceptibility genes identified for both
RA and inflammatory polyarthritis (IP) in populations
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359of northern European descent are HLA–DRB1 (7) and
PTPN22 (8). While investigations of the latter gene
suggest that it plays a role in susceptibility, rather than
outcome (9), the HLA–DRB1 gene has been associated
with disease severity in IP patients in general and in RA
patients in particular (7,10,11). A group of HLA–DRB1
alleles that share amino acid homology in the third
hypervariable region of the DR chain, collectively
referred to as the shared epitope (SE), are a broad
genetic marker that has been associated with outcomes
of RA, such as disability (10) and erosive disease (11,12).
Other studies have identified specific HLA–DRB1 geno-
types that are associated with either severe RA or
extraarticular manifestations of RA (13). For example,
both HLA–DRB1*0404 and HLA–DRB1*0401 are asso-
ciated with erosive disease (10), and homozygosity for
the HLA–DRB1*0401 genotype has been associated
with systemic organ involvement (14). Furthermore, the
genotypes HLA–DRB1*0101/*0404, *0401/*0401, and
*0401/*0404 have all been associated with vasculitis (15),
while the latter genotype has also been associated with
both Felty’s syndrome (16) and early-onset aggressive
RA in men (17).
The presence of SE alleles correlates with the
presence of both rheumatoid factor (RF) (18) and
anti–cyclic citrullinated peptide (anti-CCP) antibodies
(19), and recent studies suggest that these autoantibod-
ies, in particular, anti-CCP antibodies, are on the path-
way by which SE leads to severe disease (19). Further-
more, it has been proposed that an interaction between
smoking and the HLA–DRB1 SE alleles may trigger the
production of anti-CCP antibodies, and this may con-
tribute to the development of RA (20). All 3 of these
factors have also been shown to be independently asso-
ciated with the severity and onset of RA (7,10–12,
21–28).
There are, therefore, an increasing number of
serologic and genetic markers that may be predictive of
both the subsequent cumulative level of inflammation
and the disease severity, which in turn, is associated with
mortality. The aim of the present study was to examine
whether either the PTPN22 gene or genotypes of the
HLA–DRB1 gene, which are associated with disease
severity, are predictors of all-cause and CVD mortality
in patients with IP or RA and whether any effect is
independent of autoantibody status. The study also
aimed to examine whether the gene–environment inter-
action that results in susceptibility to RA could also
predict subsequent mortality in IP.
PATIENTS AND METHODS
Study design. We undertook a cohort analysis compar-
ing survival in patients with IP stratified by SE carrier status,
HLA–DRB1 genotype status, and PTPN22*1858T carrier status.
Study population. Patients were recruited from the
Norfolk Arthritis Register (NOAR), a primary care–based
inception cohort of patients with recent onset IP. NOAR aims
to recruit all adults ages 16 years and older who have swelling
of at least 2 joints persisting for at least 4 weeks with symptom
onset after January 1, 1989. NOAR covers the former Norwich
Health Authority and is notified of cases via general practi-
tioners or staff at hospitals within the catchment area (29).
Patients who were subsequently diagnosed by a hospi-
tal consultant as having a condition other than RA, IP,
psoriatic arthritis, or postviral arthritis, were excluded from the
study. Between 1989 and 1994, a total of 1,424 patients were
referred to NOAR who satisfied the above criteria. For this
investigation, consecutive patients recruited by NOAR within
this time period for whom a DNA sample was available were
studied (n  1,022). All patients were white.
Data collection. Data were collected by a research
nurse via a structured interview and clinical examination
shortly after registration (baseline). Demographic data col-
lected at baseline included age at symptom onset, sex, smoking
status, and time from symptom onset to presentation to
NOAR. A further assessment was performed annually until the
fifth year and then at the seventh and tenth years. At each
assessment, standard clinical variables were collected (for
details, see ref. 29). A blood sample was taken for RF,
anti-CCP, and CRP testing. RF was measured using a latex
agglutination technique, where a titer 1:40 was classified as
RF positive. Anti-CCP was tested using the Axis-Shield Diastat
kit according to the manufacturer’s instructions (Axis-Shield,
Dundee, UK), where a concentration of 5 units/ml was
classified as anti-CCP antibody positive. CRP levels (in mg/
liter) were measured using an end-point immunoturbidimetric
agglutination method. The Disease Activity Score 28-joint
assessment (DAS28) was calculated from the tender and
swollen joint counts in 28 joints and the CRP value (for
calculation methods, see http://www.das-score.nl/www.
das-score.nl/index.html). Functional disability was assessed at
baseline by having the patients complete the Health Assess-
ment Questionnaire (HAQ), as modified for use in British
patients (30). The American College of Rheumatology (ACR;
formerly, the American Rheumatism Association) 1987 crite-
ria for the classification of RA (31) were applied both cross-
sectionally at baseline and cumulatively. For the purposes of
this analysis, patients were deemed to have RA if they satisfied
the ACR criteria by the tenth-year assessment or by the time of
death, whichever was sooner.
HLA–DRB1 genotyping. HLA genotyping was per-
formed as described previously (7). Subtyping at the HLA–
DRB1 locus was performed to identify the presence of the SE,
which was defined as the presence of any of the following
alleles: HLA–DRB1*0101, *0102, *0104, *0401, *0404, *0405,
*0408,o r*1001.
PTPN22 genotyping. Genotyping of the functional
polymorphism PTPN22*C1858T (rs2476601) was undertaken
using the Sequenom platform (Sequenom, San Diego, CA)
360 FARRAGHER ET ALaccording to the manufacturer’s instructions (available at
www.sequenom.com).
Ascertainment of deaths. The Office for National
Statistics (ONS) provided details of the patients’ deaths,
including the cause and date of death. The cause of death was
coded using the International Classification of Diseases, Ninth
Revision (ICD-9) (32) until the end of 2000, and then the
Tenth Revision (ICD-10) from 2001 onward (33). For this
analysis, all codes were converted to ICD-10 codes, and the
underlying causes of death were grouped by ICD-10 chapter.
Each patient was followed up from the time of disease
symptom onset until death or until December 31, 2005,
whichever was sooner. If a patient moved from the UK or was
no longer registered with a general practitioner, the ONS
notified NOAR of the date of “embarkation.” For these
patients, followup was censored to the time of embarkation.
Statistical analysis. The association of HLA–DRB1
genotypes and the PTPN22*1858T risk allele carriage with
mortality risk was assessed using Cox proportional hazards
regression models after adjusting for age at symptom onset and
sex. The interaction between baseline RF status, anti-CCP
status, and HLA–DRB1 genotypes and PTPN22*1858T allele
carriage was assessed via Cox proportional hazards regression
models after adjusting for age at onset and sex. A similar
analysis was undertaken to assess whether associations with
genotypes were independent of the CRP value at baseline, with
patients divided according to whether the CRP was 10 mg/dl
or 10 mg/dl.
Causes of death were determined from the death
certificate. Analyses were undertaken for death from all causes
as well as for death from CVD. Death from CVD was recorded
in 2 ways: those for whom a cardiovascular condition (ICD-10
codes I00–I99) was recorded as the main underlying cause of
death and those for whom a cardiovascular condition was
mentioned anywhere on the death certificate.
Finally the interactions between SE status (0, 1, or 2 SE
alleles), smoking status at baseline (never, previous, or current
smoker), baseline anti-CCP status (negative or positive), and
mortality risk (all causes and CVD) were explored through
Cox proportional hazards regression models, adjusted by age
at symptom onset and sex. All analyses were performed using
the whole IP cohort, while the analysis between genotypes and
all-cause mortality was also performed in the subset who met
the ACR criteria for RA by 10 years or by the time of death,
if sooner. All statistical analyses were conducted using Stata
version 9 software (34).
RESULTS
Baseline characteristics of the study population.
A DNA sample was available for 1,022 IP patients, 751
of whom satisfied the ACR criteria for RA by 10 years or
by their time of death, if sooner. Their baseline charac-
teristics are shown in Table 1. As expected, markers of
Table 1. Clinical and demographic characteristics of the entire IP cohort and the RA, RF, and anti-CCP subgroups*
Characteristic
Entire IP cohort
(n  1,022)
RA subgroup
(met ACR criteria
by the tenth year)
(n  751)
IP cohort patients
RF at baseline
(n  275)
IP cohort patients
anti-CCP at
baseline
(n  204)
Age at symptom onset, median (IQR) years 54 (41–66) 55 (44–67) 57 (47–67) 57 (48–65)
No. (%) female 661 (64.7) 499 (66.4) 162 (58.9) 113 (55.4)
Symptom duration at registration, median (IQR) months 5 (2–12) 5 (2–12) 5 (2–12) 7 (3–14)
No. (%) RF positive (titer 1:40)†
At baseline 275 (29.1) 247 (35.7) 275 (100) 141 (69.1)
By the tenth year 420 (41.2) 380 (50.7) 275 (100) 176 (86.3)
No. (%) meeting ACR criteria for RA
At baseline 472 (46.2) 472 (62.9) 197 (71.6) 136 (66.7)
By the tenth year 751 (73.5) 751 (100) 247 (89.8) 186 (91.2)
CRP at baseline, median (IQR) mg/dl‡ 5 (0–15) 7 (1–19) 9 (2–23) 12 (4–32)
DAS28 at baseline, mean (95% CI) 3.95 (3.86–4.05) 4.38 (4.28–4.48) 4.25 (4.07–4.43) 4.39 (4.20–4.59)
No. (%) with anti-CCP antibodies at baseline§ 204 (27.6) 186 (35.7) 141 (70.2) 204 (100)
HAQ score at baseline, median (IQR)¶ 0.75 (0.25–1.38) 0.88 (0.38–1.63) 0.75 (0.38–1.63) 0.88 (0.38–1.63)
No. of swollen and tender joints at baseline, median
(IQR)
3 (0–8) 4 (1–10) 3 (1–9) 4 (1–9)
Smoking status at baseline, no. (%)#
Never smoked 314 (31.2) 240 (32.4) 64 (23.6) 46 (22.9)
Ex-smoker 10 years 266 (26.4) 194 (26.2) 59 (21.8) 40 (19.9)
Ex-smoker 10 years 158 (15.7) 115 (15.5) 53 (19.6) 43 (21.4)
Current smoker 268 (26.6) 192 (25.9) 95 (35.1) 72 (35.8)
*I P inflammatory polyarthritis; RA  rheumatoid arthritis; ACR  American College of Rheumatology; IQR  interquartile range; DAS28 
Disease Activity Score 28-joint assessment; 95% CI  95% confidence interval.
† Rheumatoid factor (RF) was measured in 946 patients at baseline and in 1,019 patients by the tenth year.
‡ C-reactive protein (CRP) levels were measured in 858 patients at baseline.
§ Anti–cyclic citrullinated peptide (anti-CCP) antibodies were measured in 740 patients at baseline.
¶ Health Assessment Questionnaire (HAQ) scores were determined in 1,011 patients at baseline.
# Smoking status was determined in 1,006 patients at baseline.
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and the HAQ score, were higher in the subgroups of
patients with ACR-classified RA, the RF-positive sub-
group, and the anti-CCP–positive subgroup at baseline.
An increasing frequency of SE allele carriage was
observed as the stringency of phenotype definition in-
creased. Restricting the analysis to the subgroup with
ACR-classified RA, and then to the RF-positive sub-
group, and finally, to the anti-CCP–positive subgroup
yielded increasing frequencies of patients with SE alleles
(Table 2). In contrast, only slight differences in frequen-
cies of carriage of the PTPN22*1658T susceptibility
allele were noted between these subgroups (Table 2).
Role of CRP, RF, anti-CCP, and smoking status
at baseline in predicting mortality. By December 31,
2005, a total of 242 patients (23.7%) had died. CRP
levels and smoking status at baseline were predictors of
death from all causes (Table 3). While ex-smokers did
not have an increased risk of death (hazard ratio [HR]
1.02 [95% confidence interval (95% CI) 0.73–1.43]),
compared with those who never smoked, current smok-
ers did have a higher mortality risk (HR 1.43 [95% CI
0.97–2.11]), although the difference was not statistically
significant. When the analysis was restricted to those
who satisfied the ACR criteria for RA by 10 years,
current smokers did have a significantly higher mortality
risk compared with nonsmokers (HR 1.54 [95% CI
1.00–2.38]). The duration of smoking did not appear to
have an influence on mortality risk. Compared with
those who had never smoked or those who were ex-
smokers, the estimates of the risk of mortality in smok-
ers did not increase with the number of years smoked
(categorized by tertiles). Information on the number of
cigarettes smoked per day was not collected.
The RF status and the anti-CCP status at base-
line were also predictors of death from all causes (Table
3). For example, in the IP group as a whole, the presence
of anti-CCP antibodies at baseline was a significant
predictor of mortality risk (HR 1.37 [95% CI 1.00–1.88])
as compared with the absence of anti-CCP antibodies at
baseline. The predictive value of both RF positivity and
presence of anti-CCP antibodies at baseline improved
when restricted to those who met the ACR criteria for
RA by 10 years (Table 3). However, having both anti-
CCP antibodies and RF at baseline did not confer a
higher mortality risk than having just 1 of these markers,
as compared with those who were negative for both
markers (HR 1.47 [95% CI 1.02–2.11] in the IP cohort
and HR 1.65 [95% CI 1.09–2.51] in the RA subgroup).
HLA–DRB1 and PTPN22 as predictors of death
from all causes. The influence of HLA–DRB1 and
PTPN22*1858T phenotypes on mortality risk was similar
in the entire IP cohort and in the subgroup who satisfied
the ACR criteria for RA by 10 years (Table 3). Com-
Table 2. HLA–DRB1 and PTPN22 genotypes in the entire IP cohort and in the RA, RF, and anti-CCP subgroups*
HLA–DRB1 and
PTPN22 groups
No. (%) of entire
IP cohort
(n  1,022)
No. (%) of
RA subgroup
(met ACR criteria
by the tenth year)
(n  751)
No. (%) of
IP cohort RF
at baseline
(n  275)
No. (%) of
IP cohort anti-CCP
at baseline
(n  204)
0 copies of SE alleles 416 (40.7) 288 (38.3) 81 (29.5) 40 (19.6)
1 copy of SE alleles 460 (45.0) 349 (46.5) 133 (48.4) 108 (52.9)
HLA–DRB1*01 167 (16.3) 119 (15.8) 43 (15.6) 28 (13.7)
HLA–DRB1*04 281 (27.5) 220 (29.3) 87 (31.6) 76 (37.3)
HLA–DRB1*10 12 (1.2) 10 (1.3) 3 (1.1) 4 (2.0)
2 copies of SE alleles 146 (14.3) 114 (15.2) 61 (22.2) 56 (27.5)
HLA–DRB1*01/*01 15 (1.5) 11 (1.5) 2 (0.7) 0
HLA–DRB1*01/*04 59 (5.8) 43 (5.7) 23 (8.4) 18 (8.8)
HLA–DRB1*0101/*0401 36 (3.5) 24 (3.2) 13 (4.7) 11 (5.4)
HLA–DRB1*0101/*0404 12 (1.2) 10 (1.3) 5 (1.8) 4 (2.0)
HLA–DRB1*01/*10 3 (0.3) 3 (0.4) 0 0
HLA–DRB1*04/*04 63 (6.2) 52 (6.9) 34 (12.4) 37 (18.1)
HLA–DRB1*0401/*0401 16 (1.6) 14 (1.9) 7 (2.5) 7 (3.4)
HLA–DRB1*0401/*0404 33 (3.2) 26 (3.5) 22 (8.0) 22 (10.8)
HLA–DRB1*04/*10 6 (0.6) 5 (0.7) 2 (0.7) 1 (0.5)
PTPN22*1858T allele
Negative 608 (77.1) 435 (77.5) 138 (73.8) 121 (72.5)
Positive 181 (22.9) 126 (22.5) 49 (26.2) 46 (27.5)
* Common genotype combinations are shown below the broad subtype combinations. IP  inflammatory polyarthritis; RA 
rheumatoid arthritis; RF  rheumatoid factor; anti-CCP  anti–cyclic citrullinated peptide; ACR  American College of
Rheumatology; SE  shared epitope.
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SE alleles had an increased risk of death from all causes,
both in the whole IP cohort (HR 1.55 [95% CI 1.08–
2.24]) and in the subgroup with ACR-classified RA (HR
1.54 [95% CI 1.03–2.31]) (Table 3). There was no
increased risk in those with only 1 SE allele.
When looking at the broad groups (Table 3),
patients with an HLA–DRB1*01/*04 combination had
double the mortality risk compared with those carrying 0
or 1 SE allele (HR 1.99 [95% CI 1.24–3.19] in the entire
IP cohort). In order to explore this further, we under-
took a more detailed genotype analysis. The frequency
of the common genotype combinations in the 146 pa-
tients who carried 2 SE alleles is shown in Table 2 and
the resultant HRs in Table 3. Carriage of HLA–
DRB1*0101/*0404 was associated with the highest mor-
tality risk; this was most marked in those who satisfied
the ACR criteria for RA by 10 years (HR 3.30 [95% CI
1.03–10.57]). Furthermore, carriage of HLA–
DRB1*0401/0401 was also associated with an increased
mortality risk in the entire IP cohort (HR 2.63 [95% CI
1.22–5.64]).
No association between PTPN22*1858T allele
carriage and the risk of death from all causes was
detected.
HLA–DRB1 and PTPN22 as predictors of death
from CVD. CVD was the main cause of death in 76 of
the 242 patients who died (31.4%), while in a further 48
patients (overall total of 51.2%), CVD was mentioned
elsewhere on the death certificate. The majority of
Table 3. Risk of death from all causes in the entire IP cohort and in the RA subgroup, by clinical characteristics and HLA–DRB1 and PTPN22
genotypes*
Group
Entire IP cohort
(n  1,022)
RA subgroup (met ACR criteria by
the tenth year) (n  751)
No. of patients HR (95% CI) No. of patients HR (95% CI)
CRP at baseline
10 mg/dl (comparator) 580 1.00 382 1.00
10 mg/dl 278 1.56 (1.19–2.06) 242 1.66 (1.22–2.26)
Smoking status at baseline
Never smoked (comparator) 314 1.00 240 1.00
Ex-smoker 424 1.02 (0.73–1.43) 309 1.07 (0.73–1.56)
Current smoker 268 1.43 (0.97–2.11) 192 1.54 (1.00–2.38)
Never smoked or ex-smoker at baseline (comparator) 738 1.00 549 1.00
First tertile of smoking duration at baseline (0–25 years) 95 1.41 (0.50–3.96) 61 1.45 (0.45–4.71)
Second tertile of smoking duration at baseline (26–39 years) 84 1.53 (0.80–2.93) 59 1.43 (0.64–3.19)
Third tertile of smoking duration at baseline (40–68 years) 87 1.39 (0.99–1.94) 70 1.49 (1.03–2.15)
RF titer at baseline
1:40 (comparator) 671 1.00 445 1.00
1:40 275 1.61 (1.24–2.1) 247 1.74 (1.30–2.34)
Anti-CCP antibodies at baseline
No (comparator) 536 1.00 335 1.00
Yes 204 1.37 (1.00–1.88) 186 1.50 (1.04–2.15)
SE alleles
0 copies of SE alleles (comparator) 416 1.00 288 1.00
1 copy of SE alleles 460 0.98 (0.74–1.30) 349 0.96 (0.70–1.32)
2 copies of SE alleles 146 1.55 (1.08–2.24) 114 1.54 (1.03–2.31)
0 or 1 SE allele (comparator) 876 1.00 637 1.00
2 SE alleles 146 1.57 (1.13–2.19) 114 1.58 (1.10–2.27)
0 or 1 SE allele (comparator) 876 1.00 637 1.00
HLA–DRB1*01/*01 15 1.89 (0.70–5.11) 11 1.74 (0.55–5.48)
HLA–DRB1*01/*04 59 1.99 (1.24–3.19) 43 2.25 (1.34–3.79)
HLA–DRB1*0101/*0401 36 1.66 (0.94–2.92) 24 1.72 (0.90–3.27)
HLA–DRB1*0101/*0404 12 3.00 (0.94–9.52) 10 3.30 (1.03–10.57)
HLA–DRB1*04/*04 63 1.26 (0.75–2.09) 52 1.15 (0.65–2.03)
HLA–DRB1*0401/*0401 16 2.63 (1.22–5.64) 14 2.38 (1.04–5.45)
HLA–DRB1*0401/*0404 33 0.96 (0.47–1.96) 26 0.83 (0.36–1.88)
PTPN22*1858T allele
Negative (comparator) 608 1.00 435 1.00
Positive 181 1.07 (0.73–1.55) 126 0.76 (0.47–1.21)
* Data were adjusted for age at symptom onset and sex. IP  inflammatory polyarthritis; RA  rheumatoid arthritis; ACR  American College
of Rheumatology; HR  hazard ratio; 95% CI  95% confidence interval; CRP  C-reactive protein; RF  rheumatoid factor; anti-CCP 
anti–cyclic citrullinated peptide; SE  shared epitope.
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tors of death from all causes were also predictors of
death from CVD, and the risk of death was higher for
CVD than for all causes (Table 4). For example, com-
pared with patients who had 0 or 1 SE allele, the CVD
mortality risk in those carrying the HLA–DRB1*01/*04
combination was increased over 3-fold (HR 3.03 [95%
CI 1.37–6.68]) (Table 4). Carriage of the DRB1*0101/
*0401 genotype was associated with the highest signifi-
cant risk of death (HR 3.58 [95% CI 1.52–8.47] in the IP
cohort). Patients with 1 copy of the HLA–DRB1*0401
allele had a higher mortality risk, although it did not
reach statistical significance (HR 4.04 [95% CI 0.97–
16.87]). As with all-cause mortality, no relationship
between PTPN22 susceptibility allele carriage and CVD
mortality was noted.
HLA–DRB1 and PTPN22 as predictors of death
in patients positive/negative for RF and anti-CCP. An
association between the HLA–DRB1*01/*04 combina-
tion and death was seen in patients who were RF-
positive and in those who were RF-negative at baseline,
although the association was not significant in the RF-
negative group (Table 5). Compared with RF-negative
patients with 0 or 1 SE allele, RF-positive patients with
0 or 1 SE allele had a higher mortality risk (HR 1.61
[95% CI 1.21–2.15]), and in those with 2 SE alleles,
mortality risk was higher still (HR 1.97 [95% CI 1.23–
3.17]). However, the interaction term between RF status
at baseline and the presence of 0 or 1 versus 2 copies of
SE alleles was not significant (P  0.67). Again, it was a
combination of HLA–DRB1*01/*04 that gave the great-
est hazard ratios in the RF-negative individuals (HR
1.90 [95% CI 0.99–3.63]).
The association between the HLA–DRB1*01/*04
combination and mortality risk was independent of the
baseline CRP value (data not shown), but the baseline
CRP value alone was a good predictor of subsequent
death. Compared with patients whose CRP level was
10 mg/liter at baseline and who carried 0 or 1 SE allele,
there was a higher mortality risk in patients whose CRP
level was 10 mg/liter and who carried 0 or 1 SE allele
(HR 1.54 [95% CI 1.14–2.07]) or who carried 2 SE
alleles (HR 2.16 [95% CI 1.29–3.63]).
In contrast, baseline anti-CCP antibody status
showed a significant association with mortality risk only
when 2 copies of the SE alleles were also present (Ta-
ble 5).
Interaction between SE alleles, smoking status,
and anti-CCP antibody status as a predictor of death.
Complete information on smoking and anti-CCP anti-
body status at baseline was available for 728 of the IP
patients. The presence of anti-CCP antibodies at base-
line was associated with premature death from CVD
even in nonsmokers with 0 or 1 copy of the SE alleles
(HR 2.92 [95% CI 0.99–8.65]), as well as in current
smokers (HR 2.80 [95% CI 1.13–6.94]) (Table 6). The
highest risk of death from all causes was in patients who
at baseline were current smokers, had anti-CCP antibod-
ies, and carried 2 SE alleles (HR 3.57 [95% CI 1.34–
9.50]). The risk of death from CVD was substantially
higher in this group of patients (HR 7.81 [95% CI
2.63–23.22]). Furthermore, the interaction term be-
Table 4. Risk of death from CVD in patients with a cardiovascular condition listed as the main cause of death or mentioned
anywhere on the death certificate, by HLA–DRB1 genotype*
HLA–DRB1 group
No. of
patients
HR (95% CI) for cardiovascular condition
As main cause of death
(n  76)
Mentioned anywhere on death
certificate (n  124)
0 copies of SE alleles (comparator) 416 1.00 1.00
1 copy of SE alleles 460 0.87 (0.53–1.43) 1.02 (0.69–1.51)
2 copies of SE alleles 146 1.65 (0.86–3.16) 1.70 (1.02–2.83)
0 or 1 SE allele (comparator) 876 1.00 1.00
2 SE alleles 146 1.77 (0.97–3.23) 1.68 (1.06–2.67)
0 or 1 SE allele (comparator) 876 1.00 1.00
HLA–DRB1*01/*01 15 † 1.20 (0.17–8.66)
HLA–DRB1*01/*04 59 3.03 (1.37–6.68) 2.18 (1.19–3.99)
HLA–DRB1*0101/*0401 36 3.58 (1.52–8.47) 2.13 (1.10–4.14)
HLA–DRB1*0101/*0404 12 2.67 (0.36–19.78) 2.03 (0.28–14.82)
HLA–DRB1*04/*04 63 1.21 (0.48–3.01) 1.17 (0.54–2.53)
HLA–DRB1*0401/*0401 16 4.04 (0.97–16.87) 2.91 (0.71–11.97)
HLA–DRB1*0401/*0404 33 0.95 (0.30–3.04) 1.12 (0.45–2.75)
* Data were adjusted for age at symptom onset and sex. CVD  cardiovascular disease; HR  hazard ratio; 95% CI  95%
confidence interval; SE  shared epitope.
† Too few deaths to provide robust hazard ratio estimates.
364 FARRAGHER ET ALtween current smoking, anti-CCP antibody positivity,
and carriage of 2 copies of SE alleles was significant
for both all-cause (P  0.03) and CVD (P  0.02)
mortality.
Calculations of study power. Power calculations
were undertaken based on sample sizes used in the all-
cause mortality analysis between smoking status, anti-CCP
antibody status, and carriage of 2 copies of SE alleles, since
this analysis had the smallest numbers of patients and
events. There was 70% power to detect a statistically
significant difference at the 5% level for most of the
subgroups shown in Table 6, as compared with the refer-
ence group. The power was lower for the 2 subgroups that
actually showed significant mortality risk: those who were
current smokers and anti-CCP positive and had 0 or 1 SE
allele (power 49.5%) or had 2 SE alleles (power 56.8%).
Table 5. Risk of death from all causes, by HLA–DRB1 and PTPN22 genotypes, in subgroups of patients with and without RF or anti-CCP at
baseline*
HLA–DRB1 and
PTPN22 groups
RF status at baseline
(n  946)
Anti-CCP status at baseline
(n  858)
Negative Positive Negative Positive
No. of
patients
HR
(95% CI)
No. of
patients
HR
(95% CI)
No. of
patients
HR
(95% CI)
No. of
patients
HR
(95% CI)
0 copies of SE alleles (comparator) 305 1.00 81 1.90 (1.23–2.93) 261 1.00 40 1.35 (0.74–2.46)
1 copy of SE alleles 293 0.97 (0.67–1.39) 133 1.42 (0.95–2.10) 229 0.78 (0.53–1.16) 108 1.03 (0.66–1.61)
2 copies of SE alleles 73 1.41 (0.81–2.46) 61 1.94 (1.17–3.24) 46 0.86 (0.39–1.91) 56 1.57 (0.896–2.77)
0 or 1 SE allele (comparator) 598 1.00 214 1.61 (1.21–2.15) 490 1.00 148 1.26 (0.89–1.80)
2 SE alleles 73 1.43 (0.85–2.42) 61 1.97 (1.23–3.17) 46 0.99 (0.46–2.13) 56 1.79 (1.05–3.04)
0 or 1 SE allele (comparator) 598 1.00 214 1.61 (1.21–2.15) 490 1.00 148 1.26 (0.89–1.80)
HLA–DRB1*01/*01 10 1.99 (0.49–8.09) 2 † 8 1.20 (0.17–8.67) 0 –
HLA–DRB1*01/*04 33 1.90 (0.99–3.63) 23 3.07 (1.49–6.31) 23 1.05 (0.42–2.59) 18 2.73 (1.18–6.29)
HLA–DRB1*0101/*0401 20 1.79 (0.87–3.7) 13 2.13 (0.79–5.79) 13 0.99 (0.36–2.72) 11 2.60 (0.95–7.10)
HLA–DRB1*0101/*0404 7 2.44 (0.34–17.63) 5 4.15 (1.01–17.04) 5 2.89 (0.40–21.08) 4 2.17 (0.30–15.72)
HLA–DRB1*04/*04 25 0.77 (0.24–2.42) 34 1.65 (0.89–3.07) 13 1.12 (0.15–8.06) 37 1.44 (0.72–2.86)
HLA–DRB1*0401/*0401 7 1.00 (0.14–7.22) 7 3.08 (1.13–8.42) 5 1.59 (0.22–11.53) 7 2.82 (0.69–11.54)
HLA–DRB1*0401/*0404 9 0.45 (0.06–3.23) 22 1.57 (0.73–3.37) 4 † 22 1.42 (0.62–3.25)
PTPN22*1858T allele
Negative (comparator) 418 1.00 138 1.50 (1.02–2.21) 369 1.00 121 1.54 (1.0–2.37)
Positive 120 1.34 (0.85–2.12) 49 1.14 (0.60–2.16) 106 1.25 (0.77–2.05) 46 1.23 (0.63–2.39)
* Data were adjusted for age at symptom onset and sex. RF  rheumatoid factor; anti-CCP  anti–cyclic citrullinated peptide; HR  hazard ratio;
95% CI  95% confidence interval; SE  shared epitope.
† Too few deaths to provide robust hazard ratio estimates.
Table 6. Risk of death from all causes and from CVD, by anti-CCP status, in the entire IP cohort (n  728) categorized by SE and smoking status*
Anti-CCP group
0 or 1 SE allele (n  627) 2 SE alleles (n  101)
Never smoked Ex-smoker Current smoker Never smoked Ex-smoker Current smoker
Anti-CCP, no. of patients
Absent 162 202 117 16 15 15
Present 31 57 58 15 26 14
Death from all causes, HR (95% CI)
Anti-CCP
No 1.00 (comparator) 1.08 (0.65–1.81) 1.30 (0.68–2.49) 2.55 (0.76–8.57) 0.94 (0.22–4.02) 0.63 (0.14–2.75)
Yes 1.51 (0.67–3.4) 1.02 (0.53–1.94) 2.03 (1.06–3.86) 0.76 (0.18–3.24) 2.12 (0.93–4.83) 3.57 (1.34–9.50)
Death from CVD, HR (95% CI)
Anti-CCP
No 1.00 (comparator) 1.35 (0.65–2.81) 1.09 (0.39–3.06) 2.85 (0.62–13.21) 1.80 (0.39–8.24) 0.54 (0.07–4.44)
Yes 2.92 (0.99–8.65) 1.49 (0.64–3.47) 2.80 (1.13–6.94) 0.73 (0.09–5.70) 2.08 (0.57–7.62) 7.81 (2.63–23.22)
* Only inflammatory polyarthritis (IP) patients with complete information on smoking and anti–cyclic citrullinated peptide (anti-CCP) antibody
status at baseline were included in the analysis. Data were adjusted for age at symptom onset and sex. CVD  cardiovascular disease; SE  shared
epitope; HR  hazard ratio; 95% CI  95% confidence interval.
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This study is the first to show that HLA–DRB1
genotype predicts both all-cause and CVD mortality in
patients with IP recruited from primary care settings.
The findings were similar in the IP group as a whole and
in the subgroup who met the ACR criteria for RA. The
presence of 2 copies of SE alleles, in particular, the
HLA–DRB1*01/*04 combination and homozygosity for
the HLA–DRB1*0401 alleles, was associated with high
hazard ratios for mortality. The effect sizes were higher
for death from CVD than for death from all causes. No
association between carriage of PTPN22*1858T suscep-
tibility alleles and either all-cause mortality or CVD
mortality was demonstrated.
The mechanism by which SE homozygosity pro-
motes increased mortality rates is not clear, although
previous studies have shown that compound heterozy-
gosity is associated with more severe disease, extraar-
ticular manifestations, and vasculitis in RA patients
(11,14,15). We have shown that the combination of
HLA–DRB1*04 with HLA–DRB1*01 is associated with
death from CVD and from all causes. This particular SE
genotype has previously been associated with radio-
graphic progression (35) and an increased requirement
for joint replacement (14). Such outcomes reflect more
severe disease, and therefore, our findings support the
hypothesis that it is the increased inflammatory disease
burden that promotes premature death in patients with
IP. Although the baseline CRP level was predictive of
both all-cause and CVD mortality, there was an addi-
tional effect conferred by carriage of 2 copies of SE
alleles.
Our findings are consistent with the results of a
previous investigation of associations between HLA–
DRB1 genotype combinations and endothelial dysfunc-
tion, a critical early step in the development of atheroma
(36). In that study, 2 copies of SE alleles, as compared
with 0 or 1 copy, and the presence of the HLA–
DRB1*0404 SE allele in particular was associated with
endothelium-dependent vasodilatation.
Other explanations for our findings can be con-
sidered. It is possible that certain HLA genotypes may
promote the production of specific T cells, and inheri-
tance of 2 RA-associated HLA–DRB1 alleles may in-
crease the production of these cells (37). The T cell
repertoire in patients with RA shows less diversity, with
the resultant emergence of dominant epitopes. For
example, CD8 large granular lymphocytes as well as
CD4,CD28
null T cells are more common in RA pa-
tients, particularly those with extraarticular disease, and
the latter T cells are also found in patients without RA
who have acute coronary syndromes (13,37). It is possi-
ble that these T cells are directly involved in vascular
wall damage. Both activated T cells and T cell lympho-
kines have been identified in atherosclerotic plaques,
and furthermore, expression of class II major histocom-
patibility complex molecules by smooth muscle cells on
the atherosclerotic intima, but not in the normal artery,
has been demonstrated (38). These findings support the
hypothesis that the SE may promote death from CVD by
enabling T cell–mediated vascular damage and inflam-
mation.
If the latter scenario were true, one might expect
to find evidence of a link between HLA–DRB1 variants
and CVD mortality rates in the general population,
since SE homozygosity occurs at a reasonable frequency
(7). However, previous whole genome scans of families
with coronary artery disease have revealed no evidence
of linkage to the HLA region (39,40). An association has
been observed between lipoprotein(a) levels, infection,
and certain HLA–DRB1 genotypes (41), but another
small study found no association between HLA–DRB1
genotypes and coronary artery disease (38).
Recent reports have proposed that possession of
the SE predisposes to both the susceptibility to IP and
the severity of IP, and RA in particular, by creating a
permissive environment for the production of anti-CCP
antibodies (42). This idea is based first on studies
showing that anti-CCP antibodies correlate better with
disease severity markers than with the presence of SE
alleles. Second, citrullinated peptides are bound with
higher affinity to SE alleles, and this, in turn, is associ-
ated with increased activation of CD4 T cells (43).
These findings raise the question of whether the primary
association with death from CVD may be with the
anti-CCP antibody status. Indeed, seropositivity for RF
(highly correlated with the presence of anti-CCP anti-
bodies in RA patients) in patients without arthritis has
been reported to be associated with death from CVD
(44). However, a recent cross-sectional study of RA
patients found that RF, but not anti-CCP antibodies,
was associated with mortality (45). In the current pro-
spective study, we confirmed that both RF and anti-CCP
antibodies are associated with premature death. How-
ever, the risk of premature death was increased when
anti-CCP antibodies were present in patients with a
background of smoking and carriage of 2 copies of SE
alleles. Thus, in addition to increasing susceptibility to
RA, we have now shown that this combination is also
associated with a very high risk of premature death from
366 FARRAGHER ET ALall causes, and death from CVD in particular, in patients
with IP and RA.
It is interesting to note the similarities in the
frequencies of carriage of the PTPN22*1658T suscepti-
bility allele across the different serologic groups, which
we subsequently found did not predict mortality. This is
in contrast to most previous studies that showed an
association between PTPN22 and anti-CCP antibodies
(46,47). The similar frequencies irrespective of anti-CCP
status might explain why no association was found for
carriage of PTPN22*1858T susceptibility alleles and
either all-cause mortality or CVD mortality.
Because this study used a primary care–based
cohort of patients with IP, selection bias was limited.
Furthermore, the sample size was large, and patients
were followed up for long periods of time, and so, we
were able to produce robust estimates of the influence of
HLA–DRB1 and PTPN22*1858T on the risk of death.
For some of the analyses, particularly for the mortality
risk estimate between smoking, anti-CCP antibody sta-
tus, and carriage of 2 copies of SE alleles, the numbers
of patients and subsequent deaths were small, and this
could result in less-precise estimates. Since the mortality
risks were calculated with multivariate models using
interaction terms, the potential loss in the robustness of
any of the estimates was reduced; furthermore, based on
the power calculations, we are confident that this sub-
group analysis did not show false-negative results.
Analyses were undertaken in the IP cohort as a
whole as well as in the subgroup who met the ACR
criteria for RA by 10 years. It could be argued that the
start of followup for the RA subgroup should begin at
the time of the RA diagnosis (i.e., when they met the
ACR criteria). However, we have previously shown that
it is difficult to distinguish those who will subsequently
have RA by applying the ACR criteria in the early weeks
and months following symptom onset (48). Further-
more, while some patients might not have met the ACR
criteria for a number of years, we hypothesize that the
disease processes that would contribute to the increased
mortality risk would begin at symptom onset irrespective
of the subsequent RA status. Therefore, followup in all
patients began at symptom onset.
A potential limitation of the current study could
be the exclusion of patients from the analyses either
because they were enrolled in NOAR but did not
provide a DNA sample (n  402) or because they were
lost to followup by the ONS (n  5), but only if these 407
patients were systematically different from the 1,022
patients who were included in the study. However, no
systematic differences in clinical characteristics between
the two groups were detected.
The serologic markers used in the analyses were
obtained at baseline, and it is possible that in patients
with early disease, seroconversion may subsequently
occur. This is particularly true in the case of RF, and
indeed, in the current cohort, 145 patients became
seropositive for RF between their baseline and tenth
anniversary assessments. However, the purpose of this
study was to identify factors at baseline that could be
used to predict which patients are at highest risk of
subsequent premature death.
In conclusion, we found that HLA–DRB1 geno-
types previously associated with vasculitis and extraar-
ticular disease in RA were associated with premature
death in patients with IP. This effect was independent of
RF and CRP, but an interaction with smoking and
anti-CCP antibodies substantially increased the risk of
death. This knowledge could facilitate a targeted pre-
vention program for CVD in patients with IP and RA.
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